Zhejiang Issues Guidance to Boost Biopharmaceutical Industry, Targeting Cluster Revenue Above RMB 500 Billion
The General Office of the Zhejiang Provincial People's Government has issued guidance to promote high-quality development of the biopharmaceutical industry, covering work from 2026 to 2030 with 22 measures across seven areas. By 2030, the province aims for research and development spending by above-scale biopharmaceutical enterprises to equal about 7% of operating revenue, achieve major breakthroughs in key generic technologies and frontier fields, and lift cluster operating revenue above RMB 500 billion.
The General Office of the Zhejiang Provincial People's Government recently issued the Guiding Opinions on Promoting the High-Quality Development of the Biopharmaceutical Industry. The opinions set out work for the period from 2026 to 2030 and propose 22 measures across seven areas.
The opinions state that by 2030, the province will strive for research and development expenses of above-scale biopharmaceutical enterprises to account for about 7% of their operating revenue, achieve important breakthroughs in key generic technologies and frontier leading fields, and push the operating revenue of the biopharmaceutical industry cluster above RMB 500 billion.
Why this event matters
The event has a measured impact on 4 industrys. The strongest current signal is positive for Biotechnology, with intensity 70/100 and 70% confidence over a long term horizon.
Biotechnology
- Direction
- positive
- Intensity
- 70
- Confidence
- 70%
- Horizon
- Long term
Pharmaceuticals
- Direction
- positive
- Intensity
- 65
- Confidence
- 70%
- Horizon
- Long term
Pharmaceutical R&D Services
- Direction
- positive
- Intensity
- 60
- Confidence
- 65%
- Horizon
- Long term
Traditional Chinese Medicine
- Direction
- positive
- Intensity
- 50
- Confidence
- 60%
- Horizon
- Long term
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.